Novel Surgical Interventions in the Treatment of nAMD and DME

Author(s)/Faculty: Carl D. Regillo, MD, FACS; Lejla Vajzovic, MD, FASRS
Release Date: 8/31/2022Expiration Date: 8/30/2023
Credit Type: CMENumber of Credits: 1.25
Content Type: ArticleProvider:
Reducing the treatment burden of patients receiving anti-vascular endothelial growth factor (VEGF) therapies for retinal vascular diseases remains a high priority. Loss of adherence due to frequent dosing schedules has contributed to suboptimal visual acuity outcomes in these patients. The evolution of gene therapy and sustained delivery devices offer the potential for significant reductions in treatment frequency while enhancing visual acuity outcomes. However, gene therapy and sustained delivery devices do require unique surgical approaches to provide optimal efficacy and safety outcomes. In this continuing medical education activity, experts in the field review novel surgical interventions to improve outcomes by reducing treatment burden, assess surgical processes and techniques when utilizing the Port Delivery System with ranibizumab, as well as evaluate gene therapy in patients with retinal vascular diseases.